Acuitas CEO Dr Thomas Madden and NanoVation co-founder and president Dr Dominik Witzigmann discuss how LNP engineering is expanding genetic medicine applications to traditionally undruggable targets.
|Articles|October 2, 2015
- BioPharm International-10-15-2015
- Volume 2015 eBook
- Issue 2
Innovations in Automation—High-Throughput Dynamic Light Scattering for Screening Biotherapeutic Formulations
Author(s)Daniel Some, Russell Burge
This article introduces the technology that powers automated HT–DLS and explores its practical applications in enhancing formulation stability investigations.
Advertisement
BioPharm International
eBooks Volume 28, Issue 14
Assessing a drug candidate’s suitability during preformulation is essential to minimize the risk of costly downstream failure. Stability is a defining feature of biotherapeutic performance; measuring formulation stability during early-phase screening allows developers to make robust predictions of suitability for further development. Read this article and other articles in
BioPharm International
's 2015
eBook.
Articles in this issue
almost 11 years ago
Fluctuating Capacity and Demand Conditions in Biomanufacturingalmost 11 years ago
Cleaning Validation for Biologicsalmost 11 years ago
Automation of Single-Use Systemsalmost 11 years ago
Are Biopharma Patents Poised on the Post-Grant Chopping Block?almost 11 years ago
Raising the Bar for Biopharma TrainingAdvertisement
Related to this article
Johnson & Johnson's modeling projects 18.5-year life expectancy with Tecvayli-Darzalex versus 4.9 years for standard care.
BIIE CEO Dr Stephen Wilson outlines rapid growth plans and a multidisciplinary technology stack targeting global clinical translation.
FDA's new rule formally recognizes non-animal methods like organoids and AI models as valid ways to support human drug testing.
Daiichi Sankyo and Merck pulled ifinatamab deruxtecan's FDA filing in small cell lung cancer after a 187-patient trial fell short.
IPEC’s EIP user guide streamlines information exchange and response times while increasing accuracy through standardization.
Insulin efsitora alfa-gobe (Onswik) cuts injections from 365 to 52 a year for adults with type 2 diabetes, per its new FDA approval.
Genentech is paying Earendil Labs $55 million upfront in a deal worth over $1.5 billion to develop bispecific antibodies for hard-to-treat cancers.
Advertisement
Advertisement